Servier Launches $21.50/Share Tender Offer for Day One Biopharmaceuticals (DAWN)

The Offer

Servier S.A.S., the French pharmaceutical company, has signed a definitive agreement to acquire Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) for $21.50 per share in an all-cash tender offer valued at approximately $2.5 billion. The merger agreement, dated March 6, 2026, calls for Servier's merger subsidiary (Servier Detroit Inc.) to launch a tender offer for all outstanding shares, followed by a second-step merger at the same price for any shares not tendered. Day One is a commercial-stage oncology company best known for tovorafenib (OJEMDA), the first FDA-approved therapy for pediatric low-grade glioma.

The $21.50 offer price represents a 68% premium over DAWN's $12.80 closing price on March 5, 2026 — the last unaffected trading day — and an 86% premium to the one-month volume-weighted average price. Day One's board of directors unanimously recommends that shareholders tender their shares. The stock now trades at $21.27, just $0.23 below the offer, reflecting high market confidence in deal completion.

Why This Is Interesting

This is a straightforward cash acquisition with a narrow spread and clean deal mechanics. No financing contingency. No CVR complexity. No competing bidders (so far). Servier is funding the entire $2.5 billion from existing cash and investments, which removes the single biggest execution risk in most tender offers. The board is unanimously on board, and the only regulatory gate is U.S. antitrust clearance under Hart-Scott-Rodino — a manageable hurdle for a deal involving a French pharma acquirer and a U.S. biotech with less than $200 million in annual revenue.

The current spread of about 1.1% over what could be a two-to-three-month holding period is thin. For merger arbitrage players, the annualized return depends entirely on how fast the tender offer commences and closes. If it wraps up by late May, you're looking at roughly 4-5% annualized on a relatively low-risk position. The risk/reward is tilted in favor of completion, but the upside is modest. This is more of a "park cash in a near-certain outcome" situation than a high-premium opportunity.

Key Terms

• Offer price: $21.50 per share, all cash, no CVR or contingent consideration
• Minimum tender condition: a majority of all outstanding shares of Day One common stock
• Financing: funded entirely from Servier's existing cash and investments — no financing contingency
• Regulatory approval: U.S. antitrust clearance (HSR Act) required. No foreign regulatory approvals have been flagged as conditions
• Second-step merger: shares not tendered will be acquired at the same $21.50 per share via a back-end merger
• Termination fee: $87.7 million payable to Servier if Day One terminates under certain circumstances (e.g., to accept a superior proposal)
• Outside date: December 6, 2026, extendable by 150 days if regulatory clearance is the sole outstanding condition
• Board recommendation: Day One's board unanimously recommends shareholders tender
• Advisors: Centerview Partners (financial advisor to Day One), Fenwick & West (legal counsel to Day One), Baker McKenzie (legal counsel to Servier)

Timeline

Risks

• Antitrust review: while HSR clearance is the only identified regulatory condition, Servier already markets oncology products in the U.S. through Servier Pharmaceuticals LLC. If the FTC identifies any overlap in pediatric oncology or RAF-inhibitor markets, it could extend the review timeline. The probability of a block is low, but a second request would delay closing beyond Q2.
• Pre-commencement uncertainty: the tender offer has not formally started. Until Servier files the Schedule TO and Day One files its 14D-9, shareholders cannot actually tender shares. The timeline from announcement to commencement could stretch 2-4 weeks.
• Thin spread: at $21.27, the stock trades just $0.23 below the $21.50 offer. That leaves minimal cushion if any complication arises. A broken deal would send DAWN back toward its pre-announcement level near $12.80 — a roughly 40% decline from current prices.
• No odd-lot provision identified: this is a 100% acquisition, not a partial tender, so proration is not a factor. However, there is no special odd-lot benefit here — all shares will be acquired at the same price whether through the tender or the back-end merger.
• Superior proposal risk: the $87.7 million termination fee is roughly 3.5% of deal value, which is within the standard range but not prohibitively high. A competing bidder could emerge, though no go-shop provision has been disclosed, limiting Day One's ability to actively solicit alternatives.

This analysis is for informational purposes only and does not constitute investment advice. Read the complete filing and consult your own advisors before making any decisions.